The host-tumor immune conflict: from immunosuppression to resistance and destruction - PubMed (original) (raw)
Review
The host-tumor immune conflict: from immunosuppression to resistance and destruction
S Chouaib et al. Immunol Today. 1997 Oct.
Abstract
A successful immune response against a tumor is dependent on the cytokine repertoire present at the tumor site. Salem Chouaib and colleagues discuss evidence that, to escape the immune system, tumor cells not only produce immunosuppressive cytokines but also employ strategies involving altered susceptibility to tumor necrosis factor and Fas cytotoxic pathways and, in some circumstances, use of the Fas ligand to neutralize effector cells.
Similar articles
- On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R, Egle A, Villunger A. Greil R, et al. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review. - Fas ligand and immune evasion.
Nagata S. Nagata S. Nat Med. 1996 Dec;2(12):1306-7. doi: 10.1038/nm1296-1306. Nat Med. 1996. PMID: 8946823 No abstract available. - Fas ligand and the fate of antitumour cytotoxic T lymphocytes.
O'Connell J. O'Connell J. Immunology. 2002 Mar;105(3):263-6. doi: 10.1046/j.1365-2567.2002.01379.x. Immunology. 2002. PMID: 11918687 Free PMC article. Review. No abstract available. - Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.
Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Hallermalm K, et al. Cancer Res. 2004 Sep 15;64(18):6775-82. doi: 10.1158/0008-5472.CAN-04-0508. Cancer Res. 2004. PMID: 15374996 - Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
Li JH, Rosen D, Sondel P, Berke G. Li JH, et al. Immunology. 2002 Mar;105(3):267-77. doi: 10.1046/j.1365-2567.2002.01380.x. Immunology. 2002. PMID: 11918688 Free PMC article.
Cited by
- Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo.
Donadio AC, Remedi MM, Frede S, Bonacci GR, Chiabrando GA, Pistoresi-Palencia MC. Donadio AC, et al. Clin Exp Metastasis. 2002;19(5):437-44. doi: 10.1023/a:1016329802327. Clin Exp Metastasis. 2002. PMID: 12198772 - Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine.
Casey DG, Lysaght J, James T, Bateman A, Melcher AA, Todryk SM. Casey DG, et al. Immunology. 2003 Sep;110(1):105-11. doi: 10.1046/j.1365-2567.2003.01726.x. Immunology. 2003. PMID: 12941147 Free PMC article. - Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model.
Riediger C, Wingender G, Knolle P, Aulmann S, Stremmel W, Encke J. Riediger C, et al. J Cancer Res Clin Oncol. 2013 Dec;139(12):2097-110. doi: 10.1007/s00432-013-1532-z. Epub 2013 Oct 10. J Cancer Res Clin Oncol. 2013. PMID: 24114287 - Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes.
de Gruijl TD, Bontkes HJ, Peccatori F, Gallee MP, Helmerhorst TJ, Verheijen RH, Aarbiou J, Mulder WM, Walboomers JM, Meijer CJ, van de Vange N, Scheper RJ. de Gruijl TD, et al. Br J Cancer. 1999 Mar;79(7-8):1127-32. doi: 10.1038/sj.bjc.6690179. Br J Cancer. 1999. PMID: 10098746 Free PMC article. - Myeloid suppressor cells and immune modulation in lung cancer.
Srivastava MK, Andersson Å, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Srivastava MK, et al. Immunotherapy. 2012 Mar;4(3):291-304. doi: 10.2217/imt.11.178. Immunotherapy. 2012. PMID: 22401635 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous